NCT06871410 2026-03-24Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRoswell Park Cancer InstitutePhase 1 Recruiting26 enrolled
NCT06930352 2026-03-13Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard TherapyOhio State University Comprehensive Cancer CenterPhase 2 Not yet recruiting70 enrolled
NCT05526924 2026-03-04Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck CancerUniversity of ChicagoPhase 1 Recruiting30 enrolled